

**GE Health response re alleged advocacy campaign by Innovative Pharmaceutical Association of South Africa (IPASA) opposing South Africa's efforts to introduce intellectual property reforms aimed at increasing access to essential medicine:**

**19 February 2014**

*Business & Human Rights Resource Centre invited GE Health to respond to the following items:*

- "South African pharma firms accused of delaying patents law reforms", Guardian [UK], 17 January 2014  
<http://www.theguardian.com/world/2014/jan/17/south-african-pharma-accused-delay-patents-law-reform>
- "New leaked Merck missive reveals deep drug, medical device company opposition to South African patent reforms", KEI, 20 January 2014  
<http://keionline.org/node/1908>
- "'Genocidal' drug patent plot angers doctors, rights groups"  
<http://www.timeslive.co.za/politics/2014/01/17/genocidal-drug-patent-plot-outrages-doctors-rights-groups>
- "Leaked pharmagate emails prove big pharma involvement in scandal"  
<http://www.tac.org.za/news/leaked-pharmagate-emails-prove-big-pharma-involvement-scandal>
- "TAC, Section27 and MSF react to Pharmagate"  
<http://www.fixthepatentlaws.org/?p=823>

**Comment to Business & Human Rights Resource Centre by GE Health re alleged advocacy campaign by Innovative Pharmaceutical Association of South Africa (IPASA) to oppose South Africa's efforts to introduce intellectual property reforms aimed at increasing access to essential medicine:**

Thank...you for [the] opportunity to comment on this matter. We do not have an official comment. We stand by the IPASA statement and would refer your request for comment to the IPASA...